Natco gets approval for first Sovaldi generic in India
This article was originally published in Scrip
Natco Pharma has received regulatory approval to launch generic sofosbuvir tablets 400mg in India –the first company to get such clearance in the country.
You may also be interested in...
WHO’s prequalification of the first sofosbuvir from Gilead licensee Mylan is expected to expand access to the HCV treatment, but much will depend on donor funding priorities, say experts. Gilead hopes direct negotiations with payers in certain territories can move the access needle further.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.